SINGAPORE--March 31, 2023--Horizon Quantum Computing, a Singapore-based company building software development tools to unlock the potential of quantum computing hardware, announced today that it has raised USD 18.1 million Series A...
Marina Biotech and The Debiopharm Group Partner to Develop and Commercialize RNAi-Based Therapies for the Treatment of Bladder Cancer
News | 02. 03. 2011
Marina Biotech
The Debiopharm Group (Debiopharm), a global independent biopharmaceutical development group of companies with a main focus in oncology and serious medical conditions, and Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, announced today that they entered into an exclusive agreement concerning the development and commercialization of Marina Biotech's pre-clinical program in bladder cancer.
